Drugs / CMV-MVA Triplex Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03383055 | Nov 2018 → Jul 2021 | plasma cell myeloma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03354728 | May 2018 → Dec 2026 expected | cytomegalovirus infection, disease related to hematopoietic stem cell transplant | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-MVA Triplex Vaccine | “CMV-MVA Triplex Vaccine” NCT03354728 ↗ |
| Modality | Vaccine | “multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine” NCT03354728 ↗ |
| Route | Intramuscular | “Given IM” NCT03354728 ↗ |